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Objective
To evaluate the sensitivity of multiparametric magnetic
resonance imaging (mp-MRI) for detecting prostate cancer
foci, including the largest (index) lesions.
Patients and Methods
In all, 115 patients with biopsy confirmed prostate cancer
underwent mp-MRI before radical prostatectomy. A single
expert radiologist recorded all prostate cancer foci including
the index lesion ‘blinded’ to the pathologist’s biopsy report.
Stained whole-mount histological sections were used as the
reference standard. All lesions were contoured by an
experienced uropathologist who assessed their volume and
pathological Gleason score. All lesions with a volume of
>0.5 mL and/or pathological Gleason score of >6 were
defined as clinically significant prostate cancer. Multivariate
analysis was used to ascertain the characteristics of lesions
identified by MRI.
Results
In all, 104 of 115 index lesions were correctly diagnosed by
mp-MRI (sensitivity 90.4%; 95% confidence interval [CI]
83.5–95.1%), including 98/105 clinically significant index
lesions (93.3%; 95% CI 86.8–97.3%), among which three of
three lesions had a volume of <0.5 mL and Gleason score of
>6. Overall, mp-MRI detected 131/206 lesions including 13 of
68 ‘insignificant’ prostate cancers. The multivariate logistic
regression modelling showed that pathological Gleason score
(odds ratio [OR] 11.7, 95% CI 2.3–59.8; P = 0.003) and lesion
volume (OR 4.24, 95% CI 1.3–14.7; P = 0.022) were
independently associated with the detection of index lesions
at MRI.
Conclusions
This study shows that mp-MRI has a high sensitivity for
detecting clinically significant prostate cancer index lesions,
while having disappointing results for the detection of small-
volume, low Gleason score prostate cancer foci. Thus, mp-
MRI could be used to stratify patients according to risk,
allowing better treatment selection.
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Introduction
Prostate cancer is the most common malignancy in males
and the second cause of cancer-related death in
industrialised countries [1]. In 2012, the total incidence and
mortality of prostate cancer in 40 European countries was
estimated at 417 000 and 92 000 cases, respectively [1].
According to most widely used guidelines, high circulating
levels of PSA and/or a suspicious DRE are indications for
prostate biopsy, on which pathological evaluation is
performed [2]. PSA levels, clinical stage, and biopsy Gleason
score at diagnosis, classify patients as at low, intermediate
and high risk of clinical progression [3]. Radical
prostatectomy (RP) or radiotherapy is the ‘gold standard’ for
patients with intermediate–high risk prostate cancer; in low-
risk cases active surveillance is considered a reasonable
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option. However, both PSA measurements and TRUS-guided
biopsies have limitations affecting their ability to reliably
detect prostate cancer. Indeed, 15% of men with normal
PSA levels (≤4.0 ng/mL) have prostate cancer [4].
Conversely, conditions other than prostate cancer, such as
prostatitis and lower urinary infections, can give rise to
elevated PSA levels. As about two-thirds of men with
elevated PSA levels (>4 ng/mL) will not have prostate
cancer [5], using this method as a screening test can cause
potential harms, e.g. additional medical visits, side-effects of
prostate biopsies, anxiety, and over diagnosis leading to
overtreatment with its associated side-effects (bowel urgency,
urinary leakage, erectile dysfunction). Also, prostate biopsies
are affected by sampling limitation; even when adopting
extended schemes up to 30% of TRUS-guided biopsies will
give false negative (FN) results [6] and 40% of prostate
cancer cases will be under-staged as low risk [7,8].
Consequently, alternative options to radical treatment, such
as active surveillance, focal therapies, and chemoprevention
can be inappropriately chosen, thus failing to control disease
progression. The evidence to date is insufficient to support
the use of novel markers (e.g. prostate cancer antigen 3
[PCA3], -2pro-PSA isoform and the serine protease
transmembrane protease, serine 2 [TMPRSS2]–erythroblast
transformation-specific-related gene (ERG) translocation, etc.)
in clinical practice [9,10].
According to recent guidelines, the use of MRI is currently
limited to men with clinical suspicion of prostate cancer
that have already had one or more negative prostate
biopsies [11] and in the staging of locally advanced disease
[2]. In the near future, multiparametric MRI (mp-MRI)
could be used to select PSA-positive men for biopsy
reducing the number of unnecessary procedures,
intervention-related risks, and costs [12–14]. However, while
MRI is accurate in detecting large and/or high Gleason
score tumours, it has limitations in identifying the smaller
prostate cancer foci, which are very common, as the disease
is frequently multifocal [15,16]. Recent advances in the
understanding of prostate cancer support the theory that
disease progression and metastatisation are driven by the
largest tumour focus, the index lesion [17–21]. According to
this theory therapeutic decision-making could be heavily
influenced by the clinical relevance of index lesions, which
therefore need to be accurately assessed. In a multi-reader
study of a small group of patients, Rosenkrantz et al. [22]
reported a sensitivity and positive predictive value (PPV) of
75.9% and 82.6%, respectively, for detecting index lesions. In
view of the increasing clinical importance of index lesions
these data need to be verified on larger surgically confirmed
series.
The main aim of the present study was to assess the
sensitivity of mp-MRI for detecting index prostate cancer
lesions using whole-mount histological sections as the
reference standard. Lesion characteristics were also evaluated
by multivariate analysis.
Patients and Methods
Between April 2010 and November 2012, 143 consecutive
men with prostate cancer diagnosed by TRUS-guided core
biopsy were sent to our Institution from the same tertiary
care centre for 1.5-T mp-MRI evaluations. All patients were
candidates for RP based on systematic TRUS biopsy, PSA
values and clinical parameters. The mp-MRI was performed
at ≥6 weeks after biopsy to reduce artefacts of blood pooling
within the gland. Hormonal therapy at the time of the mp-
MRI examination was a condition for exclusion from the
study.
The study received approval by the local ethical board and
was conducted according to the principles of the Helsinki
Declaration. Participants in the study signed informed
consent forms.
MRI Protocol
The MRI studies were performed with a 1.5-T scanner (Signa
Excite HD; GE Healthcare, Milwakee, IL, USA) using a four-
channel phased array coil combined with an endorectal coil
(Medrad, Indianola, PA, USA). Routinely, just before the
beginning of the examination 20 mg butylscopolamine
bromide (Buscopan, Bohringer Ingelheim, Germany) was
injected (i.m.) to reduce bowel movements. First, T2-weighted
(T2W) images were taken to assess prostate morphology,
using the following protocol: slice-thickness, 3 mm; field of
view (FOV), 16 9 16 cm; number of excitations (NEX), 2;
acquisition matrix, 384 9 288; repetition time (TR)/echo time
(TE) ratio 3020/85, 3620/90 and 3960/110 in the axial,
coronal and sagittal plain, respectively. Second, a T1 fast
spin-echo axial sequence was taken to assess for areas of
haemorrhage within the prostate using the following protocol:
slice-thickness, 3 mm; FOV 16 9 16 cm; NEX, 2; acquisition
matrix 320 9 256; TR/TE 580/min. Three diffusion-weighted
(DW) image sequences were then obtained using axial echo
planar imaging (EPI) sequences as follows: slice-thickness,
3 mm; FOV 16 9 16 cm, matrix 128 9 128, NEX 6; TR/TE
7 000/min; b-values of 0–600, 0–1 000, 0–1 400 s/mm2.
Finally, dynamic contrast-enhanced (DCE)-MRI was
performed using an axial fast spoiled gradient-recalled-echo
(FSPGR) sequence with a temporal resolution of 13 s, after
i.v. power injection of gadobutrol (Gadovist; Bayer Pharma
AG, Berlin, Germany) at 2 mL/s, followed by a saline
solution flush. The following scanning parameters were used
for image acquisition: slice thickness, 3 mm; FOV 20 9
20 cm; matrix, 224 9 192; NEX, 0.5; TR/TE, 3.5/min. The
DCE-MRI sequence was repeated 26 times. Overall imaging
parameters satisfied the minimal scanning requirements of
the recently published European Consensus Statement [23].
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Image Analysis
All images were sent to a dedicated workstation (Advantage
Windows 4.3 or 4.4, GE Healthcare) with specialised software
for image processing for both DW and DCE-MRI images
(Functool v 4.5.3 and 7.4.01d, GE Healthcare). A single
experienced radiologist (F.R.), interpreting >500 prostate mp-
MRI studies per year, analysed all the mp-MRI examinations
that met the inclusion criteria, to identify prostate cancer foci.
The reader was informed that the patients had prostate
cancer detected by biopsy but was unaware of the
pathologist’s biopsy report, i.e. its location.
The following were considered suspicious signs for prostate
cancer in the peripheral zone (PZ): a round, oval or plaque-
like area of low signal intensity on T2W sequences; presence
of extracapsular extension signs [24], i.e. hypointense focus
bulging the contour of the prostate or crossing the prostatic
capsule with gross extension in the periprostatic fat,
asymmetry of the neurovascular bundle. Focal areas of
reduced Apparent Diffusion Coefficient (ADC:
<1.1 9 10³ mm²/s) corresponding or not to a hyperintense
signal on the DW imaging with a b-value of 1 400 s/mm²
were considered as foci suspicious for cancer [25,26] (Fig. 1).
The ADC maps were computed on the DW imaging
sequence with a b-value of 1 000 s/mm², using a
monoexponential model, and the mean ADC value was,
evaluated on a selected region of interest, drawn in order to
encompass as much of the inner aspect of the lesion as
possible without contacting the edges.
Findings in the transition zone (TZ) were considered
abnormal when a wedge-shape or elliptic ill-defined area of
low signal intensity was seen on T2W sequences that may
correspond to a hyperintense area on DW imaging. DCE-
MRI was considered positive for tumour if an asymmetric
nodular or plaque-like early intense contrast uptake was
shown in either the PZ or TZ. Time intensity curves were
considered pathological when type 3 and equivocal when of
type 2 [27,28]. However, early contrast uptake on DCE-MRI
with indefinite margins without corresponding suspicious
findings on T2W imaging and DW imaging, was considered
negative for prostate cancer.
In addition to these criteria the reader recorded on a
radiological report an overall impression for each suspected
area to be probably or highly likely to be cancer and
identified the larger lesion (i.e. index lesion) that was
topographically recorded using the 16 prostatic region scheme
(A) (B)
(C) (D)
Fig. 1 A 59-year-old man with a positive biopsy for adenocarcinoma in the left PZ with a biopsy Gleason score of 3 + 3 in one of 12 samples. The axial
T2W image (A) shows a very inhomogeneous PZ signal intensity with a nodular hypointense area identifiable in the posterior left PZ (arrow). The axial
ADC map (B) shows a corresponding area of restricted diffusion; in the same location axial DCE-MRI (C) shows a nodular early intense contrast
enhancement. Pathology (D) confirmed an aggressive adenocarcinoma (pathological Gleason score of 4 + 5) with a volume of 2.59 mL (arrow).
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provided by the European Society of Urogenital Radiology
(ESUR) guidelines [23].
To compare imaging with pathological data, PZ findings were
classified as belonging to one of three axial levels, i.e. apex,
mid-gland, and base; and to one of six additional regions, i.e.
right anterior-lateral, right posterior-lateral, and right
posterior, left anterior-lateral, left posterior-lateral, and left
posterior. TZ findings were classified as being either on the
right and/or left side.
Reference Standard
Whole-mount histological sections resected from the RP
specimens were used as the reference standards. In detail, the
prostate was cut into 3-mm thick sections; slices were
obtained perpendicular to the rear gland surface, with the
same inclination as that of the axial T2W images. Conversely,
the bases and the apices were sectioned longitudinally. Then,
5-lm sections were taken from each thick slice and stained
with haematoxylin and eosin. All samples were then assessed
for cancer foci by the same experienced uropathologist (E.B).
The lesion volume was obtained by summing the area
involved by the tumour on each contiguous slide. The
pathologist also assessed the pathological Gleason score for
each focus and in multifocal cases he recorded which of the
foci the index lesion was. The index lesion was defined as the
largest tumour focus within the prostate gland [17]; clinically
significant prostate cancer was defined as a tumour of
>0.5 mL and/or pathological Gleason score >6; consequently,
prostate cancer foci with a volume <0.5 mL and a Gleason
score <6 were defined as clinically insignificant [29]. All
malignant lesions were then contoured with a marker and
each section was scanned for comparison with MRI findings.
To finalise the reference standard a second experienced
radiologist (E.A.) matched each lesion detected by the
pathologist with the MRI findings. When the sections and
axial T2W images were not perfectly overlapped, usually due
to the modified prostate shape following fixation in
formaldehyde, the pathologist and second radiologist used TZ
adenoma nodules as landmarks to better identify the lesions
on the MRI images. Lesions that did not match were
classified as false findings on MRI.
Statistical Analysis
In the present study a patient was defined ‘true positive’ (TP)
when at least one pathologically confirmed prostate cancer
lesion was detected by MRI and as a FN when the MRI did
not detect a pathologically confirmed cancer within the
prostate gland. Accordingly, per-patient sensitivity was
defined as the number of TP findings over the total number
of positive patients. The false positive (FP) rate and PPV
were not computed in the per-patient analysis, as all patients
had TRUS-biopsy confirmed prostate cancer. Per-lesion
analysis was performed considering both only index lesions
and all prostate cancer lesions. In the per-index lesion
assessment a patient was classified as TP when the MRI-
defined index lesion exactly matched the equivalent finding at
full-mount pathology, as FN when no lesions were detected
by MRI, and as FP when the MRI-identified index lesion did
not exactly match with the full-mount pathology defined
index lesion. The PPV was defined as the number of TPs
over the total number of positive calls. Sensitivity and PPV
were also assessed on a per-lesion basis considering different
Gleason score and size thresholds, and different prostate
cancer locations (i.e. PZ vs TZ). Accordingly, a prostate
cancer lesion detected at MRI was considered a TP if it
exactly matched an equivalent finding at full-mount
pathology, a FP if it did not match with any histological
finding, and a FN when a pathologically confirmed lesion was
not detected by MRI.
The Appendix reports on the methods used to assess the
relationship between pathological Gleason score and other
patient characteristics. Multivariate analysis was used to
ascertain the characteristics of lesions identified by MRI and
is also reported in the Appendix. All statistical analysis was
performed by using R software (version 2.15.2). Significance
was assigned for a P < 0.05, when appropriate.
Results
Demographic and Pathological Characteristic of
the Study Group
We enrolled 141 of the 143 patients, as two (1%) were
excluded because they were undergoing hormonal therapy at
the time of the mp-MRI. The final analysis included 115
(81.5%) patients; 26 patients were excluded because the
reference standard was not available either because they did
not undergo RP (25/141, 18%) or because the prostate cancer
foci were not found on the excised prostate (1/141, 0.7%)
(Fig. 2). Patient characteristics and clinical information are
reported in Table 1.
141 patients
116 patients
115 patients
25 patients did not
undergo radical
prostatectomy
1 patient was
negative at
histology
Fig. 2 Study selection flow chart.
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Overall, the pathologist identified 206 cancer foci of which
138 (67%) were clinically significant lesions. Of the latter, 122
(88%) were located in the PZ and 16 (12%) in the TZ. The
median volumes of lesions according to pathological Gleason
score and prostate location are reported in Table 2. Lesions
distribution was as follows: one prostate cancer focus was
detected in 55/115 patients (48%), two in 39 (34%), three in
13 (11%), four in six (5%), while five lesions were identified
in the last two patients (2%). Multifocal disease was therefore
present in 52% of patients. In this RP cohort, 157 of 206
lesions (76.2%) had a pathological Gleason score of 3 + 3 or
3 + 4 and 176 foci (85.4%) were located in the PZ. The mean
(median; range) tumour volume was 1.3 (0.74; 0.001–20.51)
mL. The 115 index lesions included: 102 lesions (88.7%) with
a volume of >0.5 mL, three lesions (2.6%) with a volume of
<0.5 mL but with a pathological Gleason score >6, and 10
clinically insignificant lesions (8.7%), i.e. with a volume
<0.5 mL and a Gleason score ≤6 mL. Pathological Gleason
Score 3 + 3 index tumours had a significant lower median
volume than those with Gleason score 3 + 4, 4 + 3 and ≥8
(All P < 0.001). In all, 34 of the 115 index lesions were
pathological stage T3 (24 cases were T3a and 10 were T3b);
the remaining 81 index lesions were pT2.
Per-Patient Analysis
The mp-MRI detected at least one prostate cancer foci in 106
of 115 patients, yielding an overall sensitivity of 92.2% (95%
CI 85.7–96.4%). None of the FN patients had lesions with a
pathological Gleason score of ≥4 + 3. Four of the nine FN
patients had clinically insignificant lesions and one had two
prostate cancer foci of which the largest was in the TZ (size
1.26 mL; pathological Gleason score 3 + 4). The remaining
four patients had Gleason score 3 + 3 (two) and 3 + 4 (two)
clinically significant prostate cancer foci.
Per-index Lesion Analysis
The mp-MRI identified 104 of the 115 index lesions
(sensitivity of 90.4%; 95% CI 83.5–95.1%) including 98 of the
105 clinically significant index lesions (sensitivity of 93.3%;
95% CI 86.8–97.3%). Table 3 reports the per-index lesion
sensitivity of mp-MRI according to pathological Gleason
score. The mp-MRI detected all index lesions with
pathological Gleason score of 4 + 3 (22 lesions) and ≥8 (15).
The mp-MRI also detected 55 of the 59 index lesions with a
3 + 4 pathological Gleason score (sensitivity of 93.2%; 95% CI
83.5–98.1%). None of the missed lesions was stage T3. As
there were two FP findings, the PPV for index lesions was
98%.
Table 1 The patients’ demographic and clinical characteristics.
Variable Value
No. of patients included in study 115
Median (interquartile range)
Age, years 64 (60–69)
PSA level, ng/mL 6.24 (4.97–8.82)
Previous TRUS-guided biopsy sessions, n 1 (1–1)
Time between biopsy and MRI, days 85 (55–111)
Time between MRI and surgery, days 26 (8–55)
Prostate volume, mL 42.61 (35.87–57.03)
Table 2 Median volume of all lesions according to pathological Gleason score and location.
Prostate regions Number of lesions (median volume, mL)
Gleason score ≤6 Gleason score 3 + 4 Gleason score 4 + 3 Gleason score ≥8
PZ 64 (0.13) 74 (1.08) 22 (1.98) 16 (1.79)
TZ 20 (0.42) 7 (2.26) 2 (1.66) 1 (6)
Total 84 (0.16) 81 (1.25) 24 (1.98) 17 (1.93)
Table 3 Per-index lesion sensitivity of mp-MRI according to pathological Gleason score and location.
Sensitivity,% (n/N)
Gleason score ≤6 Gleason score 3 + 4 Gleason score 4 + 3 Gleason score ≥8 Total
Index lesions (n = 115)
PZ 60 (9/15) 94.3 (50/53) 100 (21/21) 100 (14/14) 91.3 (94/103)
TZ 75 (3/4) 83.3 (5/6) 100 (1/1) 100 (1/1) 83.3 (10/12)
Total 63.1 (12/19) 93.2 (55/59) 100 (22/22) 100 (15/15) 90.4 (104/115)
Clinically significant index lesions (n = 105)
>0.5 mL 66.6 (6/9) 93.1 (54/58) 100 (20/20) 100 (15/15) 93.1 (95/102)
≤0.5 mL and Gleason score ≥7 NA 100 (1/1) 100 (2/2) NA 100 (3/3)
Total 66.6 (6/9) 93.2 (55/59) 100 (22/22) 100 (15/15) 93.3 (98/105)
NA, not applicable because no cases were found.
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Among the seven clinically significant index lesions missed
at mp-MRI, six were located in the PZ. Three of the six
lesions were pathological Gleason score 3 + 4 with pattern
4 respectively of 10% in one and 20% in the last two cases;
the three remaining cases were Gleason score 3 + 3. The
index lesion of one of the three above reported patients
with a Gleason score of 3 + 4 had a volume of 2.18 mL
and a percentage of pattern 4 of 20% (Fig. 3); this was the
only case with a secondary, more aggressive lesion, but with
a smaller volume (1.85 mL and a Gleason score of 4 + 3);
the latter was correctly diagnosed at mp-MRI (Fig. 4). In
this case the missed lesion did not change the therapeutic
approach.
The only missed index lesion located in the TZ had a
pathological Gleason score of 3 + 4 with a pattern 4 of 25%.
All three clinically significant index lesions with a volume of
<0.5 mL (0.14, 0.33 and 0.41 mL) but with a pathological
Gleason score >6 (respectively 4 + 3, 4 + 3, 3 + 4) were
identified by mp-MRI (Fig. 5). Also, mp-MRI correctly
identified six of 10 clinically insignificant index lesions, i.e.
with a volume of <0.5 mL and a pathological Gleason score
≤6.
According to multivariate analysis, two index lesions
characteristics were independently associated with detection at
MRI: lesion volume (odds ratio [OR] 4.24, 95% CI 1.3–14.7;
P = 0.022) and pathological Gleason score. The odds of
detecting an index lesion with pathological Gleason score >6
was 11.7 (95% CI 2.3–59.8; P = 0.003) times that of a lesion
with a Gleason score ≤6. No other variables were statistically
significant, i.e. patient age, prostate weight, prostate volume,
PSA scores, or areas of prostatitis.
Overall Per-lesion Analysis
The mp-MRI detected 131 of the 206 prostate cancer foci,
yielding an overall per-lesion sensitivity of 63.6% (95% CI
56.6–70.2%) (Table 4). The mp-MRI correctly identified 118
of the 138 clinically significant cancer foci (sensitivity 85.5%,
95% CI 78.5–90.9%) including 107 of the 122 PZ lesions
(sensitivity 87.7%, 95% CI 80.5–93.0%) and 11 of the 16 TZ
lesions (sensitivity 68.8%, 95% CI 41.3–89.0%). Sensitivity for
clinically insignificant prostate cancer lesions was 19.1% (13
of 68, 95% CI 10.6–30.5%).
The relationship between detection at MRI and lesion features
is shown in Table 5 and in the Appendix. There was evidence
(A) (B)
(C) (D)
Fig. 3 A 63-year-old man with a positive biopsy for adenocarcinoma in the left PZ with biopsy Gleason scores of 3 + 3 and 3 + 4 in two of 12 samples.
The axial T2W image (A) shows an inhomogeneous PZ signal with a faint hypointense area in the right PZ (asterisks) corresponding to a mildly reduced
ADC value in the ADC map (B). DCE-MRI (C) shows absence of nodular early intense enhancement with a slightly diffuse enhancement and a type 2
T/I curve (not shown in the figure). The final MRI report was negative for prostate cancer foci. Pathology (D) depicted an adenocarcinoma (arrows)
corresponding to the index lesion with a volume of 2.18 mL and a pathological Gleason score of 3 + 4 with a pattern 4 of 20%.
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that the detection rate of MRI increased with increasing
Gleason score: the odds of detecting a lesion with
pathological Gleason score >6 was 3.2 (95% CI 1.2–8.5) times
that of a lesion with a Gleason score ≤6. In addition, lesions
in the PZ of the prostate were more likely to be detected than
those in central zone (OR 5.4, 95% CI 1.1–24.0; P = 0.036).
Finally, there was evidence of improved detection with
increasing lesion volume (OR 7.1, 95% CI 2.4–23.7; P <
0.001).
The mp-MRI erroneously identified as cancer five prostate
areas in an equivalent number of patients, leading to a PPV
of 96%. In four of the five cases, the FP findings belonged to
patients with at least one other significant prostate cancer
correctly identified at MRI and confirmed at histopathology.
Four of the five FPs were areas of atrophy or prostatitis.
Discussion
In the present single-centre cohort study, 90.4% of prostate
cancer index lesions were identified by mp-MRI. The
sensitivity was 93.3% when considering only clinically
significant index lesions, which were the vast majority.
Interestingly, MRI detected 83.3% of TZ index lesions, all
4 + 3 and ≥8 Gleason score index lesions, and all stage T3
cancers. As expected, high-grade and/or large index lesions
were more easily detected at mp-MRI. Conversely, the
sensitivity was 63.6% for lesions of any size and pathological
Gleason score, with a PPV of 96%. In the present study, the
good detection results for index and for clinically significant
lesions were counterbalanced by the very low sensitivity of
mp-MRI for clinically insignificant lesions (19.1%). Similarly,
other authors have reported poor sensitivity for low-volume
lesions [30]. In contrast with the results of the present study,
Rosenkrantz et al. [22] using 3-T equipment reported an
average sensitivity for index lesions of 60.2% and a PPV of
65.3% when considering an exact match with
histopathological specimens, while the sensitivity and PPV
rose to 75.9% and 82.6% respectively with an approximate
match. In addition, a recent article by Le et al. [31] examined
the performance of mp-MRI for detecting prostate cancers
confirmed on whole-mount pathology in 122 patients,
reporting an overall sensitivity of 47% and sensitivity for the
index lesion of 80%. Due to the many missed index lesions,
they highlighted the continuous need for systematic biopsy
despite increasing enthusiasm for image-guided biopsy and
possible avoidance of biopsy with MRI screening. In our
opinion, the lower sensitivity reported by Le et al. [31] is due
to their different definition of ‘index lesion’, which they
defined as the lesion with the highest Gleason grade, while in
the present study the ‘index lesion’ was defined as the lesion
(A) (B)
(C) (D)
Fig. 4 The same case shown in Fig. 3. The axial T2W image (A) shows a left PZ nodular area of decreased signal intensity (asterisks) corresponding to a
low ADC value (B). DCE-MRI (C) shows only a slight early contrast enhancement. Pathology (D) confirmed an adenocarcinoma (arrows) with a volume
of 1.85 mL and a pathological Gleason score of 4 + 3.
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with the largest volume at pathology [17]. In their series [31],
14% of smaller secondary lesions had higher Gleason scores
than the largest lesion, while in the present study there was
only one such case (0.9%). The importance of using the
tumour volume to define the index lesion was supported by
the results of our multivariate analysis.
The ability of mp-MRI to detect index lesions and the very low
sensitivity of the test for clinically insignificant lesions seen in
the present study are a good premise to bring forward a
paradigmatic shift in the PSA-based diagnostic workflow of
men with suspicion of prostate cancer. According to
epidemiological data and new insights in tumour biology, it
seems now quite plausible that localised prostate cancer should
be reclassified, as argued by Ahmed et al. [32] ‘into two
subtypes – one that can be safely ignored, or better, not
diagnosed and another that, if left untreated, would
compromise either quality or quantity of life’. Excluding
clinically insignificant cancer should limit the number of
patients undergoing radical treatments with their related
complications, reduce patient anxiety of having cancer, and
(A) (B)
(C) (D)
Fig. 5 A 64-year-old man positive for a left PZ adenocarcinoma in one of 20 samples (biopsy Gleason score 3 + 3) with a PSA level of 13 ng/mL at
diagnosis. The axial T2W image (A) shows a small hypointense area in the left PZ (arrow), corresponding to a focal low ADC value (B). DCE-MRI (C)
shows, in the same position, a focal early intense contrast enhancement. Pathology (D) confirmed a small volume aggressive adenocarcinoma
(0.33 mL with a pathological Gleason score of 4 + 3) (arrows).
Table 4 Sensitivity of mp-MRI for all prostate cancer lesions and for clinically significant lesions; data are stratified according to Gleason score and
prostate region.
Sensitivity, % (n/N)
Gleason score ≤6 Gleason score 3 + 4 Gleason score 4 + 3 Gleason score ≥8 Total
All lesions
PZ 28.1 (18/64) 85.1 (63/74) 100 (22/22) 93.7 (15/16) 67 (118/176)
TZ 30 (6/20) 71.4 (5/7) 50 (1/2) 100 (1/1) 43.3 (13/30)
Total 28.6 (24/84) 83.9 (68/81) 95.8 (23/24) 94.1 (16/17) 63.6 (131/206)
Clinically significant lesions (>0.5 mL or ≤0.5 mL and Gleason score ≥7)
PZ 70 (7/10) 85.1 (63/74) 100 (22/22) 93.7 (15/16) 87.7 (107/122)
TZ 66.6 (4/6) 71.4 (5/7) 50 (1/2) 100 (1/1) 68.8 (11/16)
Total 68.7 (11/16) 83.9 (68/81) 95.8 (23/24) 94.1 (16/17) 85.5 (118/138)
Data are percentages, numerators indicates the number of detected lesions and denominators represents the total number of lesions. PZ, Peripheral Zone; TZ, Transitional Zone. GS,
Gleason score.
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limit the costs resulting from overtreatment. In the present
study, we have shown that state-of-art prostate MRI accurately
detects dominant tumours, while insignificant secondary
lesions are missed in a large proportion of patients. We report a
sensitivity of >90% for dominant lesions, which are the main
drivers of cancer progression [17–20]. If our present results are
confirmed in larger studies, mp-MRI could be safely proposed
as a triage test in men with increased PSA levels to select
patients for TRUS biopsy. A randomised trial comparing the
cost-effectiveness of the traditional diagnostic workflow to that
of the MRI-mediated pathway would probably represent the
best methodological approach to define the role of MRI in
localised prostate cancer diagnosis. Patients with a negative
MRI study would have to undergo surveillance to detect FNs,
yielding information on negative predictive value and
specificity. The present study did not include patients with a
negative TRUS biopsy or those that did not have a biopsy.
The quality of the reference standard is a major strength of
the present study. The pathologist and a second radiologist in
consensus contoured all detectable cancer foci on the 5-lm
whole-mount histological sections and on the corresponding
axial T2W slices, to allow an exact match between MRI and
the RP specimens. In most previous work, the reference
standard for imaging was TRUS biopsy, which does not allow
exact tumour matching and may underestimate Gleason score
by up to 46% [8].
There are some potential limitations to the present study. First,
interobserver variability was not assessed as only one
experienced reader took part in the study, reporting on all MRI
examinations. However, the main aim of the present study was
to measure the sensitivity of mp-MRI in detecting localised
prostate carcinoma in day-to-day practice. Reader variability
will be addressed in an on-going multi-reader trial. Second, at
the time of reporting the reader was aware that individuals
recruited into the study all had a positive TRUS biopsy. In
principle this could have strongly biased the interpreter,
pushing him to report a finding with a lower confidence
threshold than if he had been unaware of this. Due to the trial
design, this could not be avoided. However, in our opinion, the
proposed workflow did not affect reading performance for the
following reasons. First, as reported above, lesion
correspondence was obtained by exact match; lesions that were
erroneously located in a different prostate sector were classified
as false findings. Second, the criteria we chose to define a
positive finding were not solely based on a subjective
evaluation, but were supported by semi-quantitative and
quantitative analysis. While this approach should guarantee a
more reliable definition of disease, it could limit its applicability
to MRI equipment produced by other companies.
Some authors argue that MRI of the prostate gland should be
preferably performed at 3 T. While it is probable that better
MRI quality is obtained using high field intensity due to the
higher signal to noise ratio, 3.0-T MRI is still affected by
susceptibility artefacts and more meticulous tuning is required
to obtain homogeneous fields required for high-definition
imaging [33]. Debate on whether prostate MRI still requires
endorectal coils is on-going. Recently, Turkbey et al. [34]
reported higher sensitivity of dual-coil prostate MRI
compared with non-endorectal coil MRI for detecting cancer
foci. Finally, results of clinical trials, including ours, do not
convincingly lean in favour of high-field MRI.
In conclusion, the present study shows that mp-MRI has a
high sensitivity for detecting index lesions, which further
increases for clinically significant index tumours and for the
most aggressive tumours (Gleason score >6), while it has
disappointing results for detecting small-volume low Gleason
score prostate cancer foci. Further evaluation will be needed
to assess the significance of a negative MRI and to compare
patient acceptance and cost-effectiveness of the conventional
and newly proposed diagnostic workflows.
Acknowledgements
This work was funded by the FPRC onlus - 5 9 1 000
(Pro-cure project, 2009) resources from the Italian Board of
Health.
Conflicts of Interest
The authors declare that there are no conflicts of interest.
References
1 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence
and mortality patterns in Europe: estimates for 40 countries in 2012. Eur
J Cancer 2013; 49: 1374–403
2 Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate
cancer. Part 1: screening, diagnosis, and local treatment with curative
intent-update 2013. Eur Urol 2014; 65: 124–37
Table 5 Results of multivariate logistic regression model (containing all of
explanatory variables in Table S1, full model). Data are the odds of a
lesion being correctly detected at MRI either for a 1-unit increase in the
explanatory variable (for variables on a continuous scale) or for each
category relative to the odds of baseline category (for categorical
explanatory variables).
Variable OR (95% CI) P
Patient age 0.98 (0.92–1.05) 0.682
Prostate volume 0.9 (0.85–1.06) 0.459
Prostate weight 1.0 (0.99–1.05) 0.144
Gleason score
≤6 1.0
>6 3.2 (1.2–8.5) 0.017
Lesion volume 7.1 (2.4–23.7) <0.001
T stage
T2 1.0
T3 3.44 (0.15–70.5) 0.339
PSA level 0.93 (0.80–1.09) 0.378
Prostate area
Central 1.0
Peripheral 5.4 (1.1–24.0) 0.036
© 2015 The Authors
BJU International © 2015 BJU International 9
Sensitivity of mp-MRI for detecting prostate cancer foci
3 D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome
after radical prostatectomy, external beam radiation therapy, or interstitial
radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:
969–74
4 Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate
cancer among men with a prostate-specific antigen level < or =4.0 ng per
milliliter. N Engl J Med 2004; 350: 2239–46.
5 Postma R, Schr€oder FH. Screening for prostate cancer. Eur J Cancer
2005; 41: 825–33
6 Jones JS, Patel A, Schoenfield L, Rabets JC, Zippe CD, Magi-Galluzzi C.
Saturation technique does not improve cancer detection as an initial
prostate biopsy strategy. J Urol 2006; 175: 485–8
7 Hong SK, Han BK, Lee ST et al. Prediction of Gleason score upgrading
in low-risk prostate cancers diagnosed via multi (> or = 12)-core prostate
biopsy. World J Urol 2009; 27: 271–6
8 Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between
systematic biopsies and histological features of 222 radical prostatectomy
specimens: lack of prediction of tumor significance for men with
nonpalpable prostate cancer. J Urol 2001; 166: 104–10
9 Tuma RS. New tests for prostate cancer may be nearing the clinic. J Natl
Cancer Inst 2010; 102: 752–4
10 Porpiglia F, Russo F,Manfredi M et al. The roles of multiparametric
magnetic resonance imaging, PCA3 and prostate health index-which is the
best predictor of prostate cancer after a negative biopsy? J Urol 2014; 192: 60–6
11 Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on prostate
cancer. Part 1: screening, diagnosis, and treatment of clinically localised
disease. Eur Urol 2011; 59: 61–71
12 Puech P, Rouviere O, Renard-Penna R et al. Prostate cancer diagnosis:
multiparametric MR-targeted biopsy with cognitive and transrectal US-
MR fusion guidance versus systematic biopsy – prospective multicenter
study. Radiology 2013; 268: 461–9
13 Park BK, Park JW, Park SY et al. Prospective evaluation of 3-T MRI
performed before initial transrectal ultrasound-guided prostate biopsy in
patients with high prostate-specific antigen and no previous biopsy. AJR
Am J Roentgenol 2011; 197: W876–81
14 Haffner J, Lemaitre L, Puech P et al. Role of magnetic resonance
imaging before initial biopsy: comparison of magnetic resonance imaging-
targeted and systematic biopsy for significant prostate cancer detection.
BJU Int 2011; 108: E171–8
15 Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the
prostate. Morphologic features of clinically recognized versus incidental
tumors. Cancer 1992; 70: 2313–8
16 Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT.
Relationship between clinical stage and histological zone of origin in early
prostate cancer: morphometric analysis. Br J Urol 1991; 68: 499–509
17 Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J
Med 2009; 361: 1704–6
18 Liu W, Laitinen S, Khan S et al. Copy number analysis indicates monoclonal
origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559–65
19 Stamey TA,McNeal JM,Wise AM, Clayton JL. Secondary cancers in the
prostate do not determine PSA biochemical failure in untreated men
undergoing radical retropubic prostatectomy. Eur Urol 2001; 39(Suppl. 4): 22–3
20 Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for
multifocal prostate cancer in radical prostatectomy specimens: lack of
significance of secondary cancers. J Urol 2003; 170: 459–63
21 Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A,
Emberton M. The index lesion and focal therapy: an analysis of the
pathological characteristics of prostate cancer. BJU Int 2010; 106:
1607–11
22 Rosenkrantz AB, Deng FM, Kim S et al. Prostate cancer: multiparametric
MRI for index lesion localization- a multiple-reader study. AJR Am J
Roentgenol 2012; 199: 830–7
23 Barentsz JO, Richenberg J, Clements R et al. ESUR prostate MR
guidelines 2012. Eur Radiol 2012; 22: 746–57
24 Futterer JJ. MR imaging in local staging of prostate cancer. Eur J Radiol
2007; 63: 328–34
25 Sciarra A, Barentsz J, Bjartell A et al. Advances in magnetic resonance
imaging: how they are changing the management of prostate cancer. Eur
Urol 2011; 59: 962–77
26 Vargas HA, Akin O, Franiel T et al. Diffusion-weighted endorectal MR
imaging at 3 T for prostate cancer: tumor detection and assessment of
aggressiveness. Radiology 2011; 259: 775–84
27 Kuhl CK, Mielcareck P, Klaschik S et al. Dynamic breast MR imaging:
are signal intensity time course data useful for differential diagnosis of
enhancing lesions? Radiology 1999; 211: 101–10
28 Padhani AR, Gapinski CJ, Macvicar DA et al. Dynamic contrast
enhanced MRI of prostate cancer: correlation with morphology and
tumour stage, histological grade and PSA. Clin Radiol 2000; 55: 99–109
29 Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS,
Schmid HP. Localized prostate cancer. Relationship of tumor volume to
clinical significance for treatment of prostate cancer. Cancer 1993; 71
(Suppl. 3): 933–8
30 Nakashima J, Tanimoto A, Imai Y et al. Endorectal MRI for prediction
of tumor site, tumor size, and local extension of prostate cancer. Urology
2004; 64: 101–5
31 Le JD, Tan N, Shkolyar E et al. Multifocality and prostate cancer
detection by multiparametric magnetic resonance imaging: correlation
with whole-mount histopathology. Eur Urol 2015; 67: 569–76
32 Ahmed HU, Arya M, Freeman A, Emberton M. Do low-grade and low-
volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol
2012; 13: 509–17
33 Merkle EM, Dale BM. Abdominal MRI at 3.0 T: the basics revisited. AJR
Am J Roentgenol 2006; 186: 1524–32
34 Turkbey B, Merino MJ, Gallardo EC et al. Comparison of endorectal coil
and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for
localizing prostate cancer: correlation with whole-mount histopathology.
J Magn Reson Imaging 2014; 39: 1443–8
Correspondence: Valentina Giannini, Department of
Radiology, Candiolo Cancer Institute – FPO, IRCCS, Strada
Provinciale 142 Km 3,95, 10060 Candiolo, Torino, Italy.
e-mail: valentina.giannini@ircc.it
Abbreviations: ADC, Apparent Diffusion Coefficient; DCE,
dynamic contrast-enhanced; DW, diffusion-weighted; FN,
false negative; FOV, field of view; mp-MRI, multiparametric
MRI; NEX, number of excitations; OR, odds ratio; PPV,
positive predictive value; PZ, peripheral zone; RP, radical
prostatectomy; T2W, T2-weighted; TE, echo time; TP, true
positive; TR, repetition time; TZ, transition zone.
Appendix
Statistical Analysis
Several secondary analyses were performed. First, the
correlation between the pathological Gleason score and
clinical characteristics (e.g. lesion volume, prostate volume,
PSA level) were evaluated by performing a logistic regression.
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Two models were created, in which pathological Gleason
score was treated in two different ways. First, pathological
Gleason score was considered as a continuous measurement,
then it was dichotomised into ≤6 and >6. Only index lesions
were included in this analysis.
A second analysis was performed to describe the
characteristics of index lesions correctly identified at MRI.
For this analysis, the binary response of variable of interest
was the detection by MRI of an index lesion, coded as
‘detected’ or ‘missed’. Then, data were analysed by using
multivariate logistic regression analysis. For the purpose of
this analysis, certain variables were continuous while others
were collapsed into binary categories (Table S1).
Finally, we performed the same analysis on a per-lesion level,
i.e. characteristics of lesions correctly identified at MRI were
compared with those of missed lesions by using multivariate
logistic regression. The same variable of the per-index lesion
analysis were used (Table S1). In this analysis, the
pathological Gleason score was treated in two different ways.
First, the pathological Gleason score was considered as a
continuous variable; ORs and 95% CIs were calculated for
this first model. Then, we built a model in which a
dichotomised version of pathological Gleason score was used,
i.e. pathological Gleason score ≤6 vs >6 (Table S1). The ORs
estimates for this second model were also calculated. As the
odds estimates changed slightly over the two models, only the
output of the model using the dichotomised version of
pathological Gleason score value was reported in the text and
in Table 5. Conversely, in the appendix results of both
models are reported to demonstrate consistent estimation.
To assess the validity of the mixed effects analyses, we
performed likelihood ratio tests comparing the models with
fixed effects to the null models with only the random effects.
We rejected results in which the model including fixed effects
did not differ significantly from the null model. Data were
presented as ORs and 95% CIs. The OR is interpreted as the
ratio of the odds of detection for one group (e.g. T2 score)
compared with the odds for another (e.g. T3).
Correlation Between the Pathological Gleason
Score and Clinical Characteristics
When pathological Gleason score was treated as a continuous
variable, there was evidence of a positive correlation between
increasing index lesion volume and Gleason score: the
estimated increase in Gleason score for a unit increase of
index lesion volume was 0.12 (95% CI 0.04–0.20; P < 0.001).
This finding was consistent when pathological Gleason score
was treated as a binary variable: each unit increase in index
lesion volume increased the odds of having a Gleason score
>6 by 4.2 times (95% CI 1.8–10.0; P < 0.001). There was no
evidence of a correlation between pathological Gleason score
and prostate volume (0.06, 95% CI 0.24 to 0.12;
P = 0.496).
Per-index Lesion and Per-lesion Analysis
According to the multivariate logistic regression analyses, two
index lesion characteristics were independently associated
with detection at MRI: pathological Gleason score (OR 11.7,
95% CI 2.3–59.8; P = 0.003) and lesion volume (OR 4.24,
95% CI 1.3–14.7; P = 0.022). No other variables, e.g. patient
age, prostate weight, prostate volume, PSA level, different
areas of the prostate, were statistically significant. In the
per-lesion analysis, patient age (P = 0.682), prostate weight
(P = 0.144), and prostate volume (P = 0.459) did not
significantly influence detection at MRI. Also, there was no
evidence that T3 lesions were more likely to be detected than
T2 (OR 3.44, 95% CI 0.15–70.5; P = 0.339). However, there
was evidence that the detection rate of MRI increased with
increasing pathological Gleason score. When pathological
Gleason score was treated as a continuous variable, a unit
increase in pathological Gleason score increased the odds of
detection by 2.4 times (95% CI 1.1–5.3; P = 0.035). This
finding was consistent when pathological Gleason score was
treated as a binary variable: the odds of detection of a lesion
with a pathological Gleason score of >6 was 3.2 (95% CI 1.2–
8.5) times that of a lesion with Gleason score of ≤6. Lesions
in the PZ of the prostate were more likely to be detected than
those in central zone (OR 5.4, 95% CI 1.1–24.0; P = 0.036).
Furthermore, there was evidence of improved detection with
increasing lesion volume (OR 7.1, 95% CI 2.4–23.7; P <
0.001). There was no significant interaction between lesion
detection and PSA levels (P = 0.378).
Supporting Information
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online version of this article:
Table S1 Patient and lesion characteristics used for
multivariate analysis.
© 2015 The Authors
BJU International © 2015 BJU International 11
Sensitivity of mp-MRI for detecting prostate cancer foci
